News & Updates
Filter by Specialty:
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
Fatty acid synthase (FASN) is commonly expressed in operable triple-negative breast cancer (TNBC) and is associated with a poor prognosis, but omeprazole can hamper FASN activity, which may potentially boost the efficacy of neoadjuvant chemotherapy, according to the results of a phase II study.
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021
Chlormadinone prolongs active surveillance, maintains QoL in men with prostate cancer
Use of the oral antiandrogen chlormadinone at a low dose led to improvements in persistence rate of active surveillance (AS), PSA* and testosterone levels and prostate volume, and quality of life (QoL) in men with low-risk prostate cancer (PCa), the PROSAS study has shown.
Chlormadinone prolongs active surveillance, maintains QoL in men with prostate cancer
05 Nov 2021
Nerve block may provide relief for pancreatic cancer pain
Neurolytic splanchnic nerve block (SNB) appears effective for pain control in patients with moderate-to-severe pain due to unresectable pancreatic cancer, a study has shown.
Nerve block may provide relief for pancreatic cancer pain
04 Nov 2021
RS-RARP confers better continence outcomes than conventional RARP
In prostate cancer patients, retzius-sparing robotic-assisted radical prostatectomy (RS-RARP) yields better continence outcomes compared with conventional RARP, a recent study has found.